Evidence map›Paper›PMID 29967557›Full record

ArticleActa otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale2018

Long-term outcomes of alternating chemoradiotherapy in patients with advanced nasopharyngeal cancer: a single-centre experience over the last decade.

S Saijoh, T Matsuzuka, H Sato, M Suzuki, M Ikeda, R Suzuki, Y Nakaegawa, K Omori

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 95% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

S SaijohDepartment of Otolaryngology, Fukushima Medical University, Fukushima, Japan.
T MatsuzukaDepartment of Otolaryngology, Fukushima Medical University, Fukushima, Japan.
H SatoDepartment of Radiation Oncology, Fukushima Medical University, Fukushima, Japan.
M SuzukiDepartment of Otolaryngology, Fukushima Medical University, Fukushima, Japan.
M IkedaDepartment of Otolaryngology, Fukushima Medical University, Fukushima, Japan.
R SuzukiDepartment of Otolaryngology, Fukushima Medical University, Fukushima, Japan.
Y NakaegawaDepartment of Otolaryngology, Fukushima Medical University, Fukushima, Japan.
K OmoriDepartment of Otolaryngology, Fukushima Medical University, Fukushima, Japan.
Fukushima Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

summaryWe assessed the long-term outcomes of alternating chemoradiotherapy (ACRT) using 5-fluorouracil and cisplatin (FP) in 25 patients with stage II or advanced nasopharyngeal cancer treated at our institution between April 1999 and April 2010. Median follow-up duration was 87 months (range 2-189). According to the 2009 TNM classification (UICC), six patients were in stage II, nine in stage III, and 10 in stage IV. Treatment completion, response and five-year survival rates were retrospectively assessed. ACRT was performed with a first course of chemotherapy administered followed by the initial round of radiotherapy (36 Gy). Then, a second course of chemotherapy with additional radiotherapy (20-30 Gy) was administered, followed by a final third course of chemotherapy. For chemotherapy, 5-fluorouracil (5-FU, 800 mg/m

Indexed as

ChemoradiotherapyAdolescentAdultAgedChildFemaleHumansMaleMiddle AgedNasopharyngeal NeoplasmsNeoplasm StagingRetrospective StudiesSurvival RateTime FactorsTreatment OutcomeYoung Adult5-fluorouracilAlternating chemoradiotherapyCisplatinNasopharyngeal cancer

Identifiers

PMID29967557
PMCPMC6028817
OpenAlexW2800347643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.